Definition, analyte, and limits of use
Urine melatonin sample management is end-to-end control of study design, participant preparation, urine collection, identification, measurement, processing, storage, testing, data interpretation, and disposition when assessing melatonin-related excretion or rhythmicity. Most urine methods measure the principal metabolite 6-sulfatoxymelatonin rather than treating unchanged urinary melatonin as equivalent to blood or saliva concentration. The specific analyte name, analytical method, and reporting unit must be explicit.
A first-morning void, random spot urine, overnight pooled urine, interval collection, and complete timed collection are not interchangeable specimens. A first-morning sample can summarize an overnight interval, serial bins can describe a relatively coarse rhythm, and a complete timed collection better supports interval amount or excretion-rate calculations. Longer sampling intervals generally provide lower temporal resolution. The question—total output, day-night contrast, peak phase, or change after an intervention—should determine the collection design.
Urinary results are shaped by bladder accumulation, urine output, renal function, metabolism, and collection completeness. They are not an instantaneous reading of pineal secretion and cannot be exchanged directly with plasma or saliva thresholds. Detectability does not establish that a specimen is fit for circadian phase estimation or clinical judgment. Critical quality attributes, acceptable deviations, recollection rules, residual uses, and interpretive limits should be specified before collection.
Temporal design and rhythm records
Every collection interval needs an unambiguous start and finish and a rule assigning boundary voids. Records should include scheduled and actual start and end, the time of each void, dates crossing midnight, time zone, and daylight-saving status. Labels such as “night urine” or “morning urine” do not reveal the covered duration and cannot identify missed voids, delays, or temporal misalignment caused by shift work.
If circadian phase is the objective, a prespecified series should cover enough of the target cycle, with volume and duration retained for every interval. Concentration multiplied by volume produces the interval amount, and incorporating duration produces an excretion rate. These outcomes answer different questions from concentration alone or a creatinine ratio. The time anchor, included intervals, missing-data rule, and phase-fitting model should be defined before analysis rather than moving a peak after viewing the curve.
Melatonin-related rhythmicity can be affected by light, sleep, shift work, transmeridian travel, awakening, activity, and exogenous melatonin. Actual sleep and wake, nighttime light exposure, work schedule, travel, sampling-day behavior, supplements, and relevant medicines should be recorded according to the purpose, not replaced by calendar date alone. A urinary rhythm is a time-integrated signal; without suitable control, a difference should not automatically be interpreted as a change in the endogenous circadian clock.
Participant preparation and home collection
Instructions should demonstrate containers, interval boundaries, the first void, every subsequent void, response to a missed collection, temporary storage, and return steps, with understanding confirmed by teach-back or practice. Paper or electronic diaries, time stamps, and reminders may support home collection, but device records do not replace identity checks or a completeness interview. Overnight procedures should minimize illumination, searching for materials, and prolonged awakening that could disturb sleep and the target rhythm.
Requirements for water, caffeine, alcohol, nicotine, exercise, diet, medicines, and supplements should follow the question and method validation. Participants should document deviations rather than independently stopping necessary treatment, restricting fluid unsafely, or forcing excess intake for sample consistency. Acute illness, fever, dehydration, urinary symptoms, kidney or liver conditions, pregnancy, and risk of menstrual contamination may be collected when relevant and protected as sensitive information.
Children, older adults, people with limited mobility, or those with frequent nocturia may need caregiver help, portable vessels, or an alternative design. Urine bags, commodes, catheters, diaper absorbents, and transfer devices can change recovery, contamination, and analyte measurement and therefore require prior validation and documentation. Unnecessary catheterization should not be performed for research convenience, and results from different collection devices should not be pooled without a method flag.
Identity, completeness, and analytical quality
Each primary vessel and aliquot should have a unique identifier linked to participant, visit, date, interval, specimen type, and lineage. Prelabeled empty vessels need controls against selection errors, and returns should be reconciled against diaries, labels, count, and sequence. Volumetric devices, balances, clocks, and temperature loggers should suit the expected range and undergo calibration or confirmation. Raw data should retain actual volume, duration, aliquot and remaining quantities, and every conversion.
Timed pooling should use a validated, leak-resistant vessel of suitable capacity, with protocol-defined storage after each addition. Total duration and volume should be confirmed before representative aliquots are taken after appropriate mixing. If only an aliquot from each void is retained, complete void volume should still be recorded or inability to calculate total excretion made explicit. Cooling, stabilization, centrifugation, light protection, pH adjustment, preservative, and freezing should follow the analyte, platform, and validation rather than a culture or routine-urinalysis workflow.
A missed or misassigned void, spill, leak, toilet water, feces, paper, cleaning agent, or menstrual blood requires documented quarantine, recollection, or restricted use, not estimated replacement or silent merging. The assay should be validated for selectivity, sensitivity, precision, linearity, dilution recovery, matrix effects, carryover, and stability. Comparability between immunoassay and mass spectrometry, batch bridging, results below quantification, repeats, and anomalous-profile rules should all be prespecified.
Storage, transport, and inventory traceability
Short- and long-term storage should follow the analyte, container, additive, planned duration, and stability evidence. Inventory records should capture facility, unit, rack and box location, each retrieval, thaw, opening, re-aliquot, refreeze, and remaining amount. Equipment needs monitoring, alarms, maintenance, backup power, and an emergency transfer plan. A temperature set point is not the specimen's actual experience, and “frozen” alone is not an adequate long-term history.
Transport should match preservation conditions, biological risk, and applicable requirements, using a leakproof primary vessel, secondary containment capable of holding a leak, absorbent and breakage protection, and appropriate outer packaging. Recipient readiness, arrival day, and delay plans should be confirmed before dispatch, with handoffs, time, temperature, and coolant recorded. Identity, count, seals, leakage, damage, coolant, and temperature should be checked on receipt; re-cooling does not erase an excursion.
Right-sized aliquots should be selected to reduce repeated thaw and open-container contamination. Lineage and quantity balance should connect the parent specimen, aliquots, assay consumption, returns, and destruction, while inventory checks avoid unnecessary warming. An excursion, freezer failure, or transport delay should link affected specimens, duration, investigation, corrective action, and fitness decision rather than receiving one blanket “still usable” label.
Data calculations, consent, and result boundaries
The information system should connect participant, visit, sleep and light data, each void, collection interval, total volume, aliquots, processing, location, assay batch, and calculated result. Concentration, amount, excretion rate, and creatinine-adjusted value need explicit units and formulas with raw values retained; a final graph or normalized number alone is insufficient. Time-zone conversion, boundary assignment, missing intervals, and manual corrections all require provenance.
Creatinine adjustment can reduce dilution variation in a spot sample, but creatinine itself varies with muscle mass, age, sex, diet, kidney function, and collection context. It does not automatically replace a timed excretion calculation when volume and duration are known. Different normalization strategies may change group comparisons, so the approach should be selected in advance from the research question, collection design, and population and then disclosed in reporting.
Consent should explain the burden and privacy implications of overnight or repeated collection, planned tests, retention, future research, sharing, return of results, withdrawal limits, and destruction. A research measurement is generally not a direct basis for personal diagnosis or medication decisions. Clinical use or return to a participant requires the applicable method performance, confirmation, reference interpretation, and responsibility pathway. De-identification reduces but does not eliminate re-identification risk from linked sleep, work, and health data.
Release, quality measures, and governance
Before testing or data inclusion, identity, interval completeness, actual duration, volume, contamination, processing, temperature, freeze-thaw, method batch, and consent scope should be checked against the intended use to support a fit, restricted, pending, or unfit decision. A deviating specimen retained for exploratory analysis should carry a machine-readable flag. Cases and controls, shifts, and sites should not face different acceptance standards.
Measures may include on-time completion, missed or misassigned voids, identity and label errors, unusual volume, contamination, leakage, processing delay, location error, temperature excursion, unintended thaw, transport anomaly, assay failure, repeat of a time series, and corrective-action closure. Stratification by collection design, site, population, and interval can reveal systematic problems in instructions, containers, logistics, or methods rather than punishing participants.
Governance should assign responsibilities, handoffs, and change control among the study team, participant or caregiver, collection site, carrier, repository, and testing laboratory. Changes to instructions, containers, additives, equipment, software, calculation formulas, or analytical methods need assessment, approval, training, and bridging when required. A transparent interval timeline, completeness decision, and calculation convention are what make urinary melatonin metabolites reliable tools for sleep and circadian research.